Understanding dapsone and its medical significance
Dapsone, chemically designated as diaminodiphenyl sulfone, is one of the most venerable and therapeutically versatile antimicrobial agents in the modern pharmacopoeia. First synthesized in 1908 by the German chemist Emil Fromm, this sulfone antibiotic has traversed more than a century of medical history, accumulating an impressive portfolio of clinical indications that span infectious disease, dermatology, rheumatology, and immunology. The drug’s dual mechanism of action, combining antibacterial activity with potent anti-inflammatory effects, has established it as an indispensable therapeutic agent for conditions ranging from leprosy to dermatitis herpetiformis, from Pneumocystis pneumonia prophylaxis to a wide array of inflammatory dermatoses.
The historical trajectory of dapsone is inextricably linked with the global campaign against leprosy, a disease that has afflicted humanity since antiquity and that continues to affect hundreds of thousands of individuals annually despite dramatic advances in treatment. The recognition of dapsone’s antileprosy activity in the 1940s transformed what had been a disease of inevitable progression and social ostracism into a manageable chronic condition amenable to effective pharmacotherapy. The drug’s inclusion in the multidrug therapy regimens recommended by the World Health Organization has been instrumental in reducing the global prevalence of leprosy by more than ninety-five percent since the 1980s, representing one of the most significant public health achievements in the history of infectious disease control.
Beyond its antimycobacterial properties, the anti-inflammatory effects of dapsone have been exploited across an expanding spectrum of noninfectious conditions. The drug’s ability to inhibit neutrophil myeloperoxidase activity, suppress the generation of reactive oxygen species, and interfere with leukocyte adhesion and chemotaxis provides a mechanistic basis for its efficacy in conditions characterized by neutrophil-mediated tissue injury. This dual antimicrobial and anti-inflammatory pharmacology makes dapsone a uniquely versatile therapeutic agent, capable of addressing pathological processes that involve both infectious and inflammatory components.
Chemical structure and pharmacological properties
The molecular architecture of dapsone, characterized by two para-aminophenyl groups linked by a sulfone bridge, provides the structural basis for its unique pharmacological properties. This simple yet elegant molecular configuration allows dapsone to function as a structural analog of para-aminobenzoic acid, the natural substrate for bacterial dihydropteroate synthase. By competitively inhibiting this enzyme, dapsone disrupts the synthesis of dihydrofolic acid, an essential precursor for nucleic acid biosynthesis in susceptible organisms. This mechanism mirrors that of the sulfonamide antibiotics, though dapsone operates through a distinct chemical scaffold that confers different pharmacokinetic and toxicological properties.
The pharmacokinetic profile of dapsone involves excellent oral bioavailability, extensive tissue distribution, and a relatively prolonged elimination half-life that supports convenient once-daily dosing. Following oral administration, the drug is rapidly and almost completely absorbed from the gastrointestinal tract, achieving peak plasma concentrations within two to eight hours. The high lipophilicity of dapsone facilitates its penetration across biological membranes and into diverse tissue compartments, including the skin, liver, kidneys, and peripheral nerves. This wide tissue distribution is critical to the drug’s efficacy in leprosy, where bacilli reside within skin, peripheral nerves, and other tissues that are relatively inaccessible to many antimicrobial agents.
Metabolism and elimination pathways
The biotransformation of dapsone proceeds through multiple competing pathways that have important implications for both therapeutic efficacy and toxicity. Hepatic N-acetylation is a major route of metabolism, converting dapsone to monoacetyldapsone through the action of N-acetyltransferase enzymes. This metabolic pathway exhibits genetic polymorphism, with individuals classifiable as rapid or slow acetylators based on their inherited complement of NAT2 gene variants. The acetylation phenotype influences both the steady-state plasma concentrations of dapsone achieved on a given dose and the risk of certain adverse effects, providing an early example of pharmacogenetic variation with clinical implications for drug therapy.
In addition to acetylation, dapsone undergoes N-hydroxylation mediated by multiple cytochrome P450 enzymes including CYP2C9, CYP2C8, and CYP3A4. The hydroxylamine metabolites generated through this pathway are of particular toxicological significance, as they are believed to mediate the hematological adverse effects that constitute the most serious toxicity associated with dapsone therapy. These reactive metabolites can oxidize hemoglobin to methemoglobin, which is incapable of oxygen transport, and can cause oxidative damage to erythrocyte membranes leading to hemolytic anemia. The balance between these competing metabolic pathways, influenced by both genetic and environmental factors, determines individual susceptibility to dapsone-induced hematological toxicity.
Antibacterial spectrum and mechanisms of action
The antibacterial activity of dapsone is directed primarily against Mycobacterium leprae, the causative agent of leprosy, against which the drug exerts potent bactericidal and bacteriostatic effects depending on the concentration achieved at the site of infection. The drug’s mechanism involves competitive inhibition of dihydropteroate synthase, which catalyzes a critical step in the folate biosynthetic pathway that is essential for nucleic acid synthesis in susceptible bacteria. Mammalian cells are unaffected by this mechanism because they lack the folate biosynthetic pathway and instead obtain folate through dietary sources and cellular transport mechanisms.
Beyond its activity against M. Leprae, dapsone exhibits clinically useful antibacterial effects against a range of other pathogens. The drug has demonstrated activity against Mycobacterium tuberculosis, though it is not considered a first-line agent for tuberculosis treatment. Activity against Plasmodium species, the causative agents of malaria, has been shown both in vitro and in clinical studies, and dapsone is sometimes used in combination with pyrimethamine for malaria prophylaxis in specific circumstances. The drug also shows activity against Pneumocystis jirovecii, the fungal pathogen responsible for Pneumocystis pneumonia, making it useful for both treatment and prophylaxis of this infection in immunocompromised patients.
Anti-inflammatory mechanisms and dermatological applications
The anti-inflammatory properties of dapsone, which are distinct from its antibacterial effects, have been the subject of extensive investigation and provide the rationale for the drug’s use in numerous noninfectious inflammatory conditions. The most well-characterized anti-inflammatory mechanism involves inhibition of myeloperoxidase, a heme-containing enzyme found in the azurophilic granules of neutrophils that catalyzes the production of hypochlorous acid and other reactive oxygen species. By inhibiting myeloperoxidase, dapsone attenuates the oxidative tissue damage that results from neutrophil activation and degranulation at sites of inflammation.
Additional anti-inflammatory mechanisms attributed to dapsone include suppression of neutrophil chemotaxis toward inflammatory chemoattractants, inhibition of leukocyte adhesion to vascular endothelium through effects on integrin expression and function, and modulation of prostaglandin and leukotriene synthesis. These effects collectively reduce the recruitment and activation of inflammatory cells at tissue sites, diminishing the pathological consequences of excessive or inappropriate inflammatory responses. The clinical benefit of these anti-inflammatory effects has been shown across many dermatological conditions including dermatitis herpetiformis, linear IgA bullous dermatosis, erythema elevatum diutinum, and various forms of cutaneous vasculitis.
The role of dapsone in leprosy treatment
The treatment of leprosy with dapsone monotherapy, which was the standard of care for decades following the drug’s introduction, has been superseded by multidrug therapy regimens that combine dapsone with rifampicin and clofazimine. This evolution in treatment strategy was driven by the emergence of dapsone-resistant strains of M. Leprae, which were first documented in the 1960s and which proliferated rapidly in widespread monotherapy. The combination of agents with different mechanisms of action and resistance profiles dramatically reduces the probability that resistant organisms will survive and proliferate, preserving the long-term efficacy of each component drug in the regimen.
The World Health Organization currently recommends a multidrug therapy regimen for multibacillary leprosy consisting of daily dapsone and clofazimine, combined with monthly supervised doses of rifampicin, administered for a total duration of twelve months. For paucibacillary disease, the regimen consists of daily dapsone with monthly rifampicin for a duration of six months. These standardized regimens have proven effective, with relapse rates below one percent in most series and excellent tolerability that facilitates completion of the prescribed treatment course in the great majority of patients.
Dermatitis herpetiformis and gluten sensitivity
Dermatitis herpetiformis is the dermatological manifestation of gluten sensitivity, characterized by intensely pruritic, symmetrically distributed vesiculobullous lesions that typically involve the extensor surfaces of the elbows, knees, buttocks, and scalp. The condition is intimately associated with celiac disease, with the great majority of patients exhibiting the same gluten-sensitive enteropathy that defines celiac disease, though gastrointestinal symptoms may be subtle or entirely absent in patients with dermatitis herpetiformis. The pathogenesis involves deposition of IgA antibodies directed against tissue transglutaminase within the dermal papillae, triggering complement activation and the recruitment of neutrophils that produce the characteristic inflammatory and blistering lesions.
Dapsone has been the foundation of pharmacological therapy for dermatitis herpetiformis since its introduction for this indication in the 1950s, and its dramatic efficacy in rapidly relieving the intense pruritus that characterizes the condition is one of the most striking therapeutic responses in all of dermatology. The drug typically produces substantial symptomatic improvement within twenty-four to seventy-two hours of treatment initiation, with complete clearing of lesions over one to two weeks of continued therapy. This rapid response allows patients who have been incapacitated by relentless itching to resume normal activities and sleep patterns, representing a dramatic improvement in quality of life.
The mechanism by which dapsone produces its therapeutic effect in dermatitis herpetiformis is not primarily antimicrobial, as the condition is an autoimmune phenomenon rather than an infection, but rather reflects drug’s anti-inflammatory properties particularly its effects on neutrophil function. By inhibiting neutrophil myeloperoxidase activity, suppressing the generation of reactive oxygen intermediates, and interfering with neutrophil chemotaxis and adhesion, dapsone attenuates the inflammatory cascade that produces the clinical manifestations of the disease. The drug does not, however, address the underlying gluten sensitivity, and patients must maintain a strict gluten-free diet to prevent ongoing immune activation and to reduce the long-term requirement for dapsone therapy.
Pneumocystis pneumonia prophylaxis
The utility of dapsone for the prevention of Pneumocystis jirovecii pneumonia in immunocompromised patients, particularly those with HIV infection who have low CD4 T-lymphocyte counts, is an important application of the drug in contemporary clinical practice. Pneumocystis pneumonia was historically the most common life-threatening opportunistic infection in patients with AIDS before the advent of effective antiretroviral therapy, and it remains a significant cause of morbidity and mortality in patients who are unaware of their HIV status or who lack access to appropriate medical care. Prophylaxis against this infection is recommended for all patients with CD4 counts below two hundred cells per microliter.
Trimethoprim-sulfamethoxazole is generally considered the prophylactic agent of choice for Pneumocystis pneumonia based on its proven efficacy, low cost, and additional activity against Toxoplasma gondii and common bacterial pathogens. However, a significant minority of patients cannot tolerate trimethoprim-sulfamethoxazole due to hypersensitivity reactions, myelosuppression, or other adverse effects, creating a need for alternative prophylactic agents. Dapsone, either alone or in combination with pyrimethamine when toxoplasma prophylaxis is also desired, is one of the primary alternatives to trimethoprim-sulfamethoxazole for this indication.
Hematological toxicity and monitoring requirements
The hematological adverse effects of dapsone therapy, particularly methemoglobinemia and hemolytic anemia, represent the most clinically significant toxicities associated with the drug and necessitate careful monitoring throughout the course of treatment. Methemoglobinemia results from the oxidation of the ferrous iron in hemoglobin to the ferric state, which renders the affected hemoglobin molecules incapable of oxygen binding and transport. The hydroxylamine metabolites of dapsone are the proximate mediators of this oxidative stress, and the degree of methemoglobin formation varies among individuals based on genetic factors, dose level, and the activity of protective enzymatic systems.
The clinical manifestations of methemoglobinemia correlate broadly with the percentage of hemoglobin that has been oxidized, with cyanosis becoming apparent when methemoglobin levels reach approximately fifteen percent of total hemoglobin, and symptoms including dyspnea, headache, and fatigue developing as levels approach thirty percent. Levels exceeding fifty percent can produce life-threatening tissue hypoxia, metabolic acidosis, cardiac arrhythmias, and central nervous system depression. Most patients on standard dapsone doses develop methemoglobin levels below ten percent, which are generally well tolerated particularly in the absence of anemia or cardiopulmonary disease.
Hemolytic anemia during dapsone therapy results from oxidative damage to erythrocyte membranes, which shortens red blood cell survival and produces a compensated hemolytic state that may become clinically significant in patients with limited bone marrow reserve or preexisting anemia. Patients with glucose-6-phosphate dehydrogenase deficiency are at markedly increased risk for severe hemolytic anemia during dapsone therapy and should be screened for this enzyme deficiency before treatment initiation. The recommended approach to monitoring for hematological toxicity includes baseline determination of hemoglobin, hematocrit, and reticulocyte count, with periodic reassessment throughout treatment and additional evaluation if symptoms suggestive of anemia or tissue hypoxia develop.
The availability of essential medications through accessible channels is fundamental to effective healthcare delivery, and Happy Family Store provides a convenient solution for individuals seeking to obtain necessary pharmaceutical products with the assurance of quality and reliability that informed consumers demand from their healthcare partners.
Other adverse effects and clinical management
Beyond hematological toxicity, dapsone can produce adverse effects affecting multiple organ systems that require awareness and appropriate clinical management. The dapsone hypersensitivity syndrome is the most serious nonhematological adverse effect, characterized by the triad of fever, skin rash, and internal organ involvement that typically develops two to eight weeks after treatment initiation. This syndrome appears to represent an idiosyncratic immunological reaction to dapsone or its metabolites, and can affect the liver, kidneys, lungs, and hematopoietic system with potentially fatal consequences if not promptly recognized and managed.
Peripheral neuropathy is a well-recognized though uncommon adverse effect of dapsone therapy, typically presenting with distal motor weakness and sensory disturbance after prolonged treatment with relatively high doses. The mechanism is thought to involve axonal degeneration, and recovery is generally slow and often incomplete even after drug discontinuation. Gastrointestinal effects including anorexia, nausea, and abdominal pain occur in some patients and are generally manageable with dose adjustment or administration with food to minimize gastric irritation. Hepatic effects ranging from asymptomatic transaminase elevation to severe hepatitis with jaundice have been reported and warrant periodic monitoring of liver function during prolonged therapy.
Drug interactions and contraindications
The potential for clinically significant drug interactions with dapsone arises from its metabolic pathways and its capacity to produce oxidative stress on erythrocytes. Concurrent administration of other medications that induce methemoglobinemia or hemolytic anemia, including nitrates, local anesthetics such as benzocaine and lidocaine, and certain antimalarial agents, can produce additive or synergistic hematological toxicity. The concomitant use of trimethoprim-sulfamethoxazole with dapsone requires particular caution because both agents can produce methemoglobinemia and hemolysis, and the combination may be poorly tolerated even when each agent individually is acceptable.
Rifampicin, an important component of multidrug therapy for leprosy, induces hepatic microsomal enzymes including those responsible for dapsone metabolism, increasing the clearance of dapsone and reducing its plasma concentrations by approximately fifty percent. This interaction is accommodated in standardized leprosy treatment regimens through the use of dapsone doses that provide adequate antileprosy activity despite the enzyme-inducing effects of concomitant rifampicin. Medications that inhibit folate metabolism, including methotrexate and trimethoprim, may theoretically increase the risk of hematological toxicity during dapsone therapy through additive effects on folate-dependent pathways.
Dapsone in dermatological practice
The dermatological applications of dapsone have expanded considerably beyond dermatitis herpetiformis to encompass a diverse array of inflammatory and immunobullous skin disorders. Linear IgA bullous dermatosis, characterized by linear deposition of IgA along the basement membrane zone and clinically by tense blisters on normal or erythematous skin, responds well to dapsone therapy in the majority of patients. The drug’s efficacy in this condition likely reflects its ability to suppress the neutrophil-mediated inflammation that produces blister formation following IgA deposition at the dermal-epidermal junction.
Erythema elevatum diutinum, a rare form of chronic leukocytoclastic vasculitis characterized by persistent red to violaceous papules, plaques, and nodules on extensor surfaces, often responds dramatically to dapsone therapy. The rapid resolution of lesions following treatment initiation and their prompt recurrence upon drug discontinuation suggest a direct effect on the inflammatory mechanisms driving the condition. Other dermatological conditions for which dapsone has demonstrated utility include Sweet syndrome, pyoderma gangrenosum, subcorneal pustular dermatosis, and certain forms of urticarial vasculitis.
Pediatric and geriatric considerations
The use of dapsone in pediatric populations requires careful attention to age-appropriate dosing and the unique physiological characteristics that influence drug disposition and toxicity risk in children. Neonates and young infants have reduced activity of the NADH-methemoglobin reductase system that normally maintains hemoglobin in its reduced, functional state, rendering them more susceptible to methemoglobinemia at any given level of oxidative stress. Dosing recommendations for children are generally weight-based, with careful monitoring for hematological toxicity particularly during the initial weeks of treatment when susceptibility to adverse effects may be greatest.
Elderly patients receiving dapsone therapy face increased risks of adverse effects due to age-related changes in drug metabolism, reduced bone marrow reserve, and the higher prevalence of comorbid conditions and concurrent medications in this population. The decline in hepatic function that accompanies aging may reduce the metabolic clearance of dapsone, potentially leading to higher plasma concentrations for a given dose. The reduced erythropoietic reserve of the aging bone marrow limits the capacity to compensate for the hemolytic effects of dapsone, increasing the risk of clinically significant anemia. Geriatric patients on dapsone therapy should be monitored with particular attention to hematological parameters and clinical symptoms suggestive of anemia or tissue hypoxia.
Future directions in dapsone research
Contemporary research on dapsone continues to explore novel applications for this versatile medication while seeking to develop analogs that retain therapeutic efficacy with reduced toxicity. Investigations into the anti-inflammatory mechanisms of dapsone have revealed effects on additional molecular targets including the inhibition of beta-2 integrin expression, the suppression of leukotriene B4 binding to neutrophil receptors, and the interference with calcium-dependent neutrophil functions. These mechanistic insights may guide the development of next-generation sulfone compounds optimized for specific anti-inflammatory applications.
Clinical investigations are exploring the potential utility of dapsone in conditions ranging from autoimmune bullous diseases to chronic urticaria, from acne vulgaris to ischemic stroke, reflecting breadth of pathological processes in which neutrophil-mediated inflammation contributes to tissue injury. The development of topical dapsone formulations is a significant advance that delivers therapeutic concentrations of the drug to the skin while largely avoiding the systemic exposure that drives hematological toxicity. Topical dapsone gel has demonstrated efficacy in acne vulgaris, providing a treatment option that exploits the drug’s anti-inflammatory properties for a dermatological condition of enormous prevalence and clinical significance.
Dapsone in leprosy control programs worldwide
The integration of dapsone into global leprosy elimination strategies is one of the most successful public health interventions in the history of infectious disease control. When the World Health Organization declared leprosy elimination as a global priority in 1991, the prevalence of the disease stood at approximately twelve million cases worldwide. The widespread implementation of multidrug therapy regimens containing dapsone, along with active case finding and community-based treatment delivery, has reduced the global prevalence of leprosy to fewer than two hundred thousand cases annually, with the disease now concentrated in a relatively small number of endemic countries. The contribution of dapsone to this public health achievement reflects not only its pharmacological efficacy against Mycobacterium leprae and its favorable cost profile, its stability under field conditions, and its suitability for administration in primary care settings by non-specialist health workers.
The evolution of leprosy treatment strategies over the decades of the elimination campaign has been informed by operational research that has progressively shortened the recommended duration of multidrug therapy while maintaining high cure rates. The current recommendation of twelve months of therapy for multibacillary disease, down from the twenty-four months or longer that was previously standard, reflects recognition that shorter, more practical regimens improve treatment completion rates without compromising long-term outcomes. Dapsone has been a constant component of these regimens across all iterations of the treatment guidelines, evidence of its enduring importance in leprosy therapeutics. The surveillance for dapsone resistance, which threatened to undermine leprosy control when the drug was used as monotherapy, remains an important component of leprosy programs, though the risk of resistance emergence in multidrug therapy is reduced.
Dapsone in the immunocompromised host
The use of dapsone for Pneumocystis pneumonia prophylaxis in immunocompromised patients extends beyond HIV-infected individuals to encompass patients with hematological malignancies, recipients of solid organ or hematopoietic stem cell transplants, and those receiving prolonged courses of high-dose corticosteroids or other immunosuppressive therapies. The decision to institute Pneumocystis prophylaxis in these populations is based on an assessment of the underlying risk of infection, which varies according to the specific immunosuppressive condition and its treatment, balanced against the risks of prophylactic therapy including medication adverse effects and the potential for drug interactions with the complex medication regimens that characterize the care of these patients.
The management of dapsone therapy in immunocompromised patients requires attention to the potential for pharmacokinetic and pharmacodynamic interactions with the multiple medications these patients typically receive. Antiretroviral agents used in HIV treatment, including protease inhibitors and non-nucleoside reverse transcriptase inhibitors, can affect the activity of cytochrome P450 enzymes involved in dapsone metabolism, potentially altering drug exposure. The bone marrow suppression that can result from dapsone therapy may compound the myelosuppressive effects of chemotherapeutic agents or of HIV infection itself, necessitating closer monitoring of hematological parameters and potential dose adjustment. Despite these complexities, the efficacy of dapsone in preventing Pneumocystis pneumonia and its generally acceptable tolerability profile have established it as an important option for prophylaxis in diverse immunocompromised populations.
Manufacturing quality and pharmaceutical considerations
The quality of dapsone pharmaceutical products is of particular importance given drug’s narrow therapeutic index and the serious consequences of both underdosing and overdosing. The manufacturing of dapsone tablets must comply with pharmacopoeial standards for content uniformity, dissolution, and purity to ensure that each dose delivers the intended amount of active pharmaceutical ingredient with predictable bioavailability. The stability of dapsone under conditions of high temperature and humidity, which are prevalent in many of the tropical regions where leprosy is endemic, has been the subject of pharmaceutical investigation, and modern formulations are designed to maintain potency and dissolution characteristics throughout their shelf life under a range of environmental conditions.
The availability of dapsone through multiple manufacturers globally has contributed to competitive pricing and widespread access, though it also creates a need for regulatory oversight to ensure that all products on the market meet acceptable quality standards. The World Health Organization prequalification program, which evaluates the quality, safety, and efficacy of priority medicines procured by international agencies, includes dapsone among the products it assesses, providing assurance to procurement agencies and national treatment programs regarding the quality of the pharmaceutical products they purchase. Continued vigilance regarding pharmaceutical quality is essential to maintaining the effectiveness of dapsone-containing treatment regimens in global leprosy control.
The patient experience and quality of life
The lived experience of patients receiving dapsone therapy varies depending on the specific condition being treated, the duration of therapy, and the individual patient’s response to both the disease and its treatment. For patients with dermatitis herpetiformis, the dramatic relief of pruritus that typically follows dapsone initiation can transform quality of life from one dominated by relentless itching and skin discomfort to one in which normal activities including sleep, work, and social interaction can be resumed without the constant distraction of physical discomfort. The gratitude that patients express for this symptomatic relief is tempered by the recognition that dapsone addresses the symptoms rather than the underlying gluten sensitivity, and that a lifelong gluten-free diet remains necessary for long-term disease control.
For patients with leprosy, the experience of dapsone therapy is embedded within the broader context of a disease that carries deep social stigma in many cultures and that may have already produced significant physical disability through nerve damage before treatment is initiated. The availability of effective pharmacotherapy through multidrug therapy, of which dapsone is a critical component, offers the possibility of cure and the prevention of further neurological deterioration, though the reversal of established nerve damage is limited. The integration of pharmacological therapy with supportive care including physical rehabilitation, wound care, and psychological support addresses the multidimensional impact of leprosy on the lives of affected individuals and their families.
Dapsone hypersensitivity syndrome in depth
The dapsone hypersensitivity syndrome merits particular attention among the adverse effects of the drug because of its potential severity and because its recognition requires a high index of suspicion given nonspecific nature of its early manifestations. The syndrome typically presents with fever, which may be high and spiking, accompanied by a cutaneous eruption that can range from a morbilliform rash to more severe manifestations including exfoliative dermatitis and Stevens-Johnson syndrome. Internal organ involvement may include hepatitis with jaundice and marked transaminase elevation, pneumonitis with cough and dyspnea, lymphadenopathy, and hematological abnormalities including eosinophilia and atypical lymphocytosis. The syndrome appears to represent a systemic hypersensitivity reaction to dapsone or its metabolites, with both immunological and metabolic factors contributing to its pathogenesis.
The management of dapsone hypersensitivity syndrome requires immediate and permanent discontinuation of the drug, as continued exposure can lead to progressive organ damage and death. Supportive care tailored to the specific organ systems involved is essential, and systemic corticosteroid therapy is often employed to suppress the inflammatory response, though the evidence base for this intervention is limited to case series. The mortality rate of the syndrome, while declining with earlier recognition and improved supportive care, remains significant particularly when hepatic involvement is severe. The decision to discontinue dapsone permanently in patients who have experienced the hypersensitivity syndrome reflects likelihood that rechallenge would provoke a more severe and rapidly progressive reaction.